The Asian Cardiovascular Market Outlook to 2010 is a new management report which provides comprehensive coverage of the major cardiovascular markets in the Asia Pacific region; this report provides detailed analysis of, market trends, epidemiology, current leading brands of treatment, product sales forecast and future market leaders over the period 2005-2010 in nine markets: China, India, Singapore, South Korea, Thailand, Philippines, Malaysia, Indonesia and Taiwan. The Asia Pacific region is an important market for cardiovascular products; it is estimated to have high prevalence rates for cardiovascular diseases and associated risk factors. However, due to the increasing presence of effective generic medicine and the limited launches of innovative, the threat of underperformance facing major pharmaceutical companies is now very real. Through analysis and forecasts ,this report will allow you to identify the cardiovascular market trends in developed and emerging Asian countries, assess the dominant forces driving market growth and develop potential growth and diversification opportunities in this region over the period 2005-2010
Table of Contents
The Asian Cardiovascular Market Outlook to 2010
Executive Summary
- Patient potential
- Regional healthcare and licensing trends
- Regional market analysis
- Key players in the Asian cardiovascular market
Patient potential
- Summary
- Introduction
- Disease description
- Defining patient potential
- Limitations of cardiovascular epidemiology data
- Cardiovascular risk factors
- Hypertension
- Dyslipidemia
- Diabetes
- Cardiovascular disease
- Acute thrombotic events
- Acute coronary syndromes
- Venous thromboembolism
- Stroke
Regional healthcare and licensing trends
- Summary
- Introduction
- Regional healthcare expenditure
- Healthcare financing
- The external environment
- Licensing analysis
Regional market analysis
- Summary
- Introduction
- Market breakdown by therapy area
- Market breakdown by country
- Leading products
- Anti-hypertensives
- Introduction
- Analysis of the top 10 anti-hypertensives
- Regional dynamics
- Market analysis by drug class
- ACE inhibitors
- Angiotensin receptor blockers
- Beta-blockers
- Calcium channel blockers
- Diuretics
- Anti-hypertensives sales forecasts
- Anti-dyslipidemics
- Introduction
- Analysis of the top 10 anti-dyslipidemics
- Regional dynamics
- Market analysis by drug class
- Statins
- Fibrates
- Other anti-dyslipidemics
- Anti-dyslipidemics sales forecast
- Cardiac therapies
- Introduction
- Analysis of the top 10 cardiac therapy brands
- Regional dynamics
- Market analysis by drug class
- Nitrates/nitrites
- Anti-arrhythmics
- Others
- Cardiac therapies sales forecasts
- Anti-thrombotics
- Introduction
- Analysis of the top 10 anti-thrombotics
- Regional dynamics
- Market analysis by drug class
- Heparins/low molecular weight heparins
- Vitamin K antagonists
- Oral anti-platelets
- Fibrinolytics
- Anti-thrombotic sales forecasts
Key players in the Asian cardiovascular market
- Summary
- Introduction
- Asian market shares
- Pfizer
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts
- Sanofi-Aventis
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts
- Merck & Co
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts
- AstraZeneca
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts
- Novartis
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts
- Bayer
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts
- GSK
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts
- Roche
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts
Appendix
- IMS sales data
- Glossary
- Index
List of Figures
- Figure 1.1: Relationship between cardiovascular disease and risk factors
- Figure 1.2: Risk factors associated with hypertension
- Figure 2.3: External analysis of the Asian region
- Figure 3.4: Competitive dynamics in the Asian cardiovascular market
- Figure 3.5: Competitive dynamics the top 10 selling cardiovascular products in the cardiovascular market, 2003
- Figure 3.6: Competitive dynamics of the Asian anti-hypertensive market by drug class, 2003
- Figure 3.7: Competitive dynamics the top 10 selling anti-hypertensives in the Asian region, 2003
- Figure 3.8: Competitive dynamics in the Asian anti-dyslipidemics market, 2003
- Figure 3.9: Competitive dynamics the top 10 selling anti-dyslipidemics in the Asian region, 2003
- Figure 3.10: Competitive dynamics in the Asian cardiac therapy market by drug class, 2003
- Figure 3.11: The competitive dynamics of leading brands in the cardiac therapy area in the Asian region, 2003
- Figure 3.12: Competitive dynamics in the Asian anti-thrombotic market by drug class, 2003
- Figure 3.13: Competitive dynamics of the top ten leading brands in the anti-thrombotics market, 2003
- Figure 4.14: Market share of key players in the Asian cardiovascular market, 2000 and 2004
List of Tables
- Table 1.1: Estimated prevalence of hypertension in the Asian region, 2004
- Table 1.2: Estimated prevalence of hypertension in the Asian region, 2005
- Table 1.3: Clinical guidelines for adult patients at borderline and high risk of cardiovascular disease by serum levels of lipids
- Table 1.4: Estimated prevalence of hypercholesterolemia in the Asian region, 2004
- Table 1.5: Estimated forecast prevalence of hypercholesterolemia in the Asian region, 2005
- Table 1.6: Estimated prevalence of diabetes in the Asian region, 2004
- Table 1.7: Estimated prevalence of diabetes in the Asian region, 2005
- Table 1.8: Estimated prevalence of major cardiovascular diseases in the Asian region, 2004
- Table 1.9: Estimated incidence of myocardial infarction (MI) in the Asian region, 2004
- Table 1.10: Estimated incidence of DVT in the Asian region, 2004
- Table 1.11: Estimated prevalence of stroke in the Asian region, 2004
- Table 2.12: Recent statistics on the healthcare sector in the Asian region, 2002
- Table 2.13: Public and private financing in nine Asian markets, 2002
- Table 2.14: Sales of types of cardiovascular brands in the Asian pharmaceutical market, 2000
- Table 2.15: Sales of types of cardiovascular brands in the nine major markets of the Asian region, 2004
- Table 3.16: Breakdown of the Asian cardiovascular market by major therapeutic areas, 2000
- Table 3.17: Cardiovascular sales by therapy area across the Asian region, 2004
- Table 3.18: Top 10 selling branded cardiovascular products in the Asian market, 2004
- Table 3.19: Breakdown of Asian anti-hypertensive market by drug class, 2000
- Table 3.20: Breakdown of the Asian anti-hypertensive market by leading brands, 2003
- Table 3.21: Market share of the leading classes of anti-hypertension drugs in the Asian region, 2004
- Table 3.22: Market share of the ACE inhibitor/ARB category in the Asian region, 2004
- Table 3.23: Breakdown of the ACE inhibitor class in the Asian market by leading brands, 2003
- Table 3.24: Breakdown of the ARB drug class in the Asian market by leading brands, 2003
- Table 3.25: Market share of the beta blockers drug class in the Asian region, 2004
- Table 3.26: Breakdown of the beta-blocker class in the Asian market by leading brands, 2003
- Table 3.27: Market share of the CCB drug class in the Asian region, 2004
- Table 3.28: Breakdown of the CCB class in the Asian market by leading brands, 2003
- Table 3.29: Market share of the diuretic drug class in the Asian region, 2004
- Table 3.30: Breakdown of the diuretic class in the Asian market by leading brands, 2003
- Table 3.31: Sales forecasts for hypertension drug classes in the major markets of the Asian region, 2004
- Table 3.32: Breakdown of the Asian anti-dyslipidemic market by drug class, 2000
- Table 3.33: Breakdown of the Asian anti-dyslipidemic market by leading brands, 2003
- Table 3.34: Market share of dyslipidemia class of drugs in the nine major markets of the Asian region, 2004
- Table 3.35: Sales forecasts for dyslipidemia drug classes in the Asian region, 2004
- Table 3.36: Breakdown of the Asian cardiac therapy market by drug class, 2000
- Table 3.37: Breakdown of the Asian cardiac therapy market by leading brands, 2003
- Table 3.38: Market share of cardiac therapy class drugs in the nine major markets of the Asian region, 2004
- Table 3.39: Sales forecasts for cardiac therapies drug classes in the Asian region, 2004
- Table 3.40: Breakdown of the Asian anti-thrombotic market by drug class, 2000
- Table 3.41: Breakdown of the Asian region anti-thrombotic market by leading brands, 2004
- Table 3.42: Market share of anti-thrombotics class of drugs in the nine major markets of the Asian region, 2004
- Table 3.43: Sales forecast for the anti-thrombotic drug class in the Asian region, 2004
- Table 4.44: Key players in the Asian cardiovascular market, 2000–2004
- Table 4.45: Pfizer's marketed Asian cardiovascular portfolio, 2004
- Table 4.46: Pfizer's cardiovascular R&D pipeline, 2005
- Table 4.47: Forecast sales for Pfizer's Asian cardiovascular portfolio, 2004
- Table 4.48: Sanofi-Aventis' marketed Asian cardiovascular portfolio, 2004
- Table 4.49: Sanofi-Aventis' cardiovascular R&D pipeline, 2005
- Table 4.50: Forecast sales for Sanofi-Aventis' Asian cardiovascular portfolio, 2004
- Table 4.51: Merck & Co.'s marketed Asian cardiovascular portfolio, 2004
- Table 4.52: Merck & Co.'s cardiovascular R&D pipeline, 2005
- Table 4.53: Forecast sales for Merck & Co.'s Asian cardiovascular portfolio, 2004
- Table 4.54: AstraZeneca's marketed Asian cardiovascular portfolio, 2004
- Table 4.55: AstraZeneca's cardiovascular R&D pipeline, 2005
- Table 4.56: Forecast sales for AstraZeneca's Asian cardiovascular portfolio, 2004
